CA2835819A1 - Induction of immune tolerance using methotrexate - Google Patents
Induction of immune tolerance using methotrexate Download PDFInfo
- Publication number
- CA2835819A1 CA2835819A1 CA2835819A CA2835819A CA2835819A1 CA 2835819 A1 CA2835819 A1 CA 2835819A1 CA 2835819 A CA2835819 A CA 2835819A CA 2835819 A CA2835819 A CA 2835819A CA 2835819 A1 CA2835819 A1 CA 2835819A1
- Authority
- CA
- Canada
- Prior art keywords
- methotrexate
- therapeutic
- subject
- cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract description 543
- 229960000485 methotrexate Drugs 0.000 title claims abstract description 541
- 230000006058 immune tolerance Effects 0.000 title claims description 41
- 230000006698 induction Effects 0.000 title description 7
- 238000011282 treatment Methods 0.000 claims abstract description 226
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 204
- 238000000034 method Methods 0.000 claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 37
- 229960000548 alemtuzumab Drugs 0.000 claims description 198
- 210000004027 cell Anatomy 0.000 claims description 120
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims description 116
- 102000045921 human GAA Human genes 0.000 claims description 116
- 230000001225 therapeutic effect Effects 0.000 claims description 99
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 230000001965 increasing effect Effects 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 238000002054 transplantation Methods 0.000 claims description 31
- 230000005875 antibody response Effects 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 26
- 230000005784 autoimmunity Effects 0.000 claims description 25
- 210000003289 regulatory T cell Anatomy 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 210000004698 lymphocyte Anatomy 0.000 claims description 21
- 201000006417 multiple sclerosis Diseases 0.000 claims description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 108010044091 Globulins Proteins 0.000 claims description 11
- 102000006395 Globulins Human genes 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 9
- 230000000779 depleting effect Effects 0.000 claims description 9
- 229960004641 rituximab Drugs 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 8
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 6
- 230000008102 immune modulation Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 210000005003 heart tissue Anatomy 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 102000043404 human GLA Human genes 0.000 claims description 2
- 230000004044 response Effects 0.000 abstract description 50
- 230000028993 immune response Effects 0.000 abstract description 28
- 230000001404 mediated effect Effects 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 18
- 241000699670 Mus sp. Species 0.000 description 137
- 241001465754 Metazoa Species 0.000 description 118
- 108090000174 Interleukin-10 Proteins 0.000 description 61
- 102000003814 Interleukin-10 Human genes 0.000 description 61
- 230000000694 effects Effects 0.000 description 57
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 54
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 54
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 210000000952 spleen Anatomy 0.000 description 31
- 230000003325 follicular Effects 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 21
- 230000003393 splenic effect Effects 0.000 description 21
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 20
- 102000043738 human CD52 Human genes 0.000 description 20
- 210000001165 lymph node Anatomy 0.000 description 20
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 210000003826 marginal zone b cell Anatomy 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 18
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 238000000684 flow cytometry Methods 0.000 description 17
- 210000002707 regulatory b cell Anatomy 0.000 description 17
- 230000003442 weekly effect Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 208000023275 Autoimmune disease Diseases 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 238000011740 C57BL/6 mouse Methods 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 12
- 230000007170 pathology Effects 0.000 description 12
- 230000003285 pharmacodynamic effect Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 230000000735 allogeneic effect Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000009163 protein therapy Methods 0.000 description 10
- 210000001685 thyroid gland Anatomy 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 9
- 230000036755 cellular response Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000007928 intraperitoneal injection Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 206010052779 Transplant rejections Diseases 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 210000002443 helper t lymphocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 229940124691 antibody therapeutics Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 102100025877 Complement component C1q receptor Human genes 0.000 description 5
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002641 enzyme replacement therapy Methods 0.000 description 5
- 230000003832 immune regulation Effects 0.000 description 5
- 229960000598 infliximab Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 5
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000001815 biotherapy Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 229940103023 myozyme Drugs 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001631 vena cava inferior Anatomy 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102000013135 CD52 Antigen Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 3
- 206010025327 Lymphopenia Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 231100001023 lymphopenia Toxicity 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229960005027 natalizumab Drugs 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 206010040400 serum sickness Diseases 0.000 description 3
- -1 small molecule compound Chemical class 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 102100027990 Beta/gamma crystallin domain-containing protein 2 Human genes 0.000 description 2
- 101710154736 Beta/gamma crystallin domain-containing protein 2 Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 241000551546 Minerva Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000003208 anti-thyroid effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940043671 antithyroid preparations Drugs 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 201000004502 glycogen storage disease II Diseases 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000000329 lymphopenic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 2
- 230000024664 tolerance induction Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UUVPYTIBUIBXTJ-ZDUSSCGKSA-N (2s)-2-[[4-[(2,4-diaminopteridin-7-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2C(N)=NC(N)=NC2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 UUVPYTIBUIBXTJ-ZDUSSCGKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241001133757 Carpentaria Species 0.000 description 1
- 102100034755 Centrosomal protein of 85 kDa Human genes 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100029141 Cyclic nucleotide-gated cation channel beta-1 Human genes 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 101710113609 Glutamic acid-rich protein Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101100383049 Homo sapiens CD52 gene Proteins 0.000 description 1
- 101000945822 Homo sapiens Centrosomal protein of 85 kDa Proteins 0.000 description 1
- 101000877379 Homo sapiens ETS-related transcription factor Elf-3 Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010051792 Infusion related reaction Diseases 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 101150111548 SH3BGRL3 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 101710120939 Tissue-resident T-cell transcription regulator protein ZNF683 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 229960004593 alglucosidase alfa Drugs 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920000547 conjugated polymer Polymers 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000005338 frosted glass Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486697P | 2011-05-16 | 2011-05-16 | |
| US61/486,697 | 2011-05-16 | ||
| PCT/US2012/036405 WO2012158362A1 (en) | 2011-05-16 | 2012-05-03 | Induction of immune tolerance by using methotrexate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2835819A1 true CA2835819A1 (en) | 2012-11-22 |
Family
ID=47177257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2835819A Abandoned CA2835819A1 (en) | 2011-05-16 | 2012-05-03 | Induction of immune tolerance using methotrexate |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20140135337A1 (OSRAM) |
| EP (2) | EP3824890A1 (OSRAM) |
| JP (3) | JP6174572B2 (OSRAM) |
| KR (3) | KR102316283B1 (OSRAM) |
| CN (4) | CN103648501A (OSRAM) |
| AU (1) | AU2012256281B2 (OSRAM) |
| BR (1) | BR112013029501A2 (OSRAM) |
| CA (1) | CA2835819A1 (OSRAM) |
| CL (1) | CL2013003298A1 (OSRAM) |
| CO (1) | CO6841993A2 (OSRAM) |
| DO (1) | DOP2013000268A (OSRAM) |
| EC (1) | ECSP13013081A (OSRAM) |
| ES (1) | ES2836823T3 (OSRAM) |
| GT (1) | GT201300278A (OSRAM) |
| IL (2) | IL229245B (OSRAM) |
| MA (1) | MA35165B1 (OSRAM) |
| MX (1) | MX2013013445A (OSRAM) |
| MY (1) | MY173304A (OSRAM) |
| NI (1) | NI201300121A (OSRAM) |
| PE (1) | PE20140469A1 (OSRAM) |
| PH (1) | PH12013502256A1 (OSRAM) |
| PT (1) | PT2709627T (OSRAM) |
| RU (1) | RU2674036C2 (OSRAM) |
| SG (1) | SG194802A1 (OSRAM) |
| TN (1) | TN2013000472A1 (OSRAM) |
| UA (1) | UA117556C2 (OSRAM) |
| WO (1) | WO2012158362A1 (OSRAM) |
| ZA (1) | ZA201308315B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011139379A2 (en) * | 2010-05-06 | 2011-11-10 | Duke University | A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
| CN118370823A (zh) * | 2013-05-03 | 2024-07-23 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
| US20140356361A1 (en) * | 2013-06-04 | 2014-12-04 | Selecta Biosciences, Inc. | Repeated administration of non-immunosuppressive antigen specific immunotherapeutics |
| WO2016037162A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| IL255010B2 (en) | 2015-04-15 | 2024-01-01 | Regeneron Pharma | Methods of increasing strength and functionality with gdf8 inhibitors |
| JP2016213236A (ja) * | 2015-04-30 | 2016-12-15 | 日東電工株式会社 | 半導体装置用フィルム、及び、半導体装置の製造方法 |
| HUE072005T2 (hu) | 2017-03-11 | 2025-10-28 | Cartesian Therapeutics Inc | Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények |
| US11944628B2 (en) * | 2017-05-12 | 2024-04-02 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| TWI821227B (zh) * | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
| KR20220139936A (ko) | 2020-02-08 | 2022-10-17 | 젠자임 코포레이션 | 폼페병을 치료하기 위한 조성물 및 방법 |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4558690A (en) | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| US5108987A (en) | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| DE4000154A1 (de) | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| CA2559188C (en) | 2004-03-05 | 2013-01-08 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
| US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
| EP1988882B1 (en) * | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2008094937A2 (en) | 2007-01-29 | 2008-08-07 | Joslin Diabetes Center, Inc. | Methods of modulating angiogenesis |
| WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| EP2077281A1 (en) * | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| JP5856481B2 (ja) | 2008-10-08 | 2016-02-09 | ケンブリッジ・エンタープライズ・リミテッド | 多発性硬化症の二次性自己免疫疾患の診断および治療についての方法ならびに組成物 |
| CA2742910A1 (en) | 2008-11-07 | 2010-05-14 | 4Sc Ag | Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease |
| CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
-
2012
- 2012-05-03 CA CA2835819A patent/CA2835819A1/en not_active Abandoned
- 2012-05-03 KR KR1020207027913A patent/KR102316283B1/ko active Active
- 2012-05-03 RU RU2013155618A patent/RU2674036C2/ru active
- 2012-05-03 CN CN201280035299.3A patent/CN103648501A/zh active Pending
- 2012-05-03 ES ES12785624T patent/ES2836823T3/es active Active
- 2012-05-03 MY MYPI2013003998A patent/MY173304A/en unknown
- 2012-05-03 PE PE2013002499A patent/PE20140469A1/es not_active Application Discontinuation
- 2012-05-03 CN CN202011422509.7A patent/CN113209288A/zh active Pending
- 2012-05-03 KR KR1020197033979A patent/KR102163285B1/ko active Active
- 2012-05-03 SG SG2013082003A patent/SG194802A1/en unknown
- 2012-05-03 UA UAA201314626A patent/UA117556C2/uk unknown
- 2012-05-03 PH PH1/2013/502256A patent/PH12013502256A1/en unknown
- 2012-05-03 JP JP2014511390A patent/JP6174572B2/ja active Active
- 2012-05-03 PT PT127856243T patent/PT2709627T/pt unknown
- 2012-05-03 MX MX2013013445A patent/MX2013013445A/es unknown
- 2012-05-03 CN CN201811398468.5A patent/CN109620830A/zh active Pending
- 2012-05-03 CN CN201910138372.3A patent/CN110124039A/zh active Pending
- 2012-05-03 KR KR1020137032882A patent/KR20140040744A/ko not_active Ceased
- 2012-05-03 AU AU2012256281A patent/AU2012256281B2/en active Active
- 2012-05-03 EP EP20197579.4A patent/EP3824890A1/en active Pending
- 2012-05-03 US US14/116,486 patent/US20140135337A1/en not_active Abandoned
- 2012-05-03 EP EP12785624.3A patent/EP2709627B1/en active Active
- 2012-05-03 WO PCT/US2012/036405 patent/WO2012158362A1/en not_active Ceased
- 2012-05-03 BR BR112013029501A patent/BR112013029501A2/pt not_active Application Discontinuation
-
2013
- 2013-11-04 IL IL229245A patent/IL229245B/en active IP Right Grant
- 2013-11-06 ZA ZA2013/08315A patent/ZA201308315B/en unknown
- 2013-11-13 TN TNP2013000472A patent/TN2013000472A1/fr unknown
- 2013-11-14 NI NI201300121A patent/NI201300121A/es unknown
- 2013-11-14 GT GT201300278A patent/GT201300278A/es unknown
- 2013-11-15 CL CL2013003298A patent/CL2013003298A1/es unknown
- 2013-11-15 DO DO2013000268A patent/DOP2013000268A/es unknown
- 2013-12-04 MA MA36522A patent/MA35165B1/fr unknown
- 2013-12-05 CO CO13286019A patent/CO6841993A2/es not_active Application Discontinuation
- 2013-12-13 EC ECSP13013081 patent/ECSP13013081A/es unknown
-
2017
- 2017-03-03 JP JP2017040046A patent/JP6381707B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145564A patent/JP6694020B2/ja active Active
-
2020
- 2020-03-24 US US16/828,407 patent/US11672802B2/en active Active
- 2020-08-23 IL IL276879A patent/IL276879B/en unknown
-
2023
- 2023-04-28 US US18/141,128 patent/US20230372347A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230372347A1 (en) | Induction of immune tolerance by using methotrexate | |
| Kishimoto | Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies | |
| Warner et al. | ABO-incompatible solid-organ transplantation | |
| US20210236512A1 (en) | Clozapine for the treatment of a immunoglobulin driven b cell disease | |
| HK40053503A (en) | Induction of immune tolerance using methotrexate | |
| HK40053628A (en) | Induction of immune tolerance by using methotrexate | |
| NZ716716B2 (en) | Induction of immune tolerance by using methotrexate | |
| HK40012743A (en) | Induction of immune tolerance by using methotrexate | |
| OA16781A (en) | Induction of immune tolerance by using methotrexate. | |
| HK1194668B (en) | Induction of immune tolerance by using methotrexate | |
| HK1194668A (en) | Induction of immune tolerance by using methotrexate | |
| HK40007634A (en) | Induction of immune tolerance by using methotrexate | |
| NZ617575B2 (en) | Induction of immune tolerance by using methotrexate | |
| NZ742216B2 (en) | Induction of immune tolerance by using methotrexate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170502 |
|
| FZDE | Discontinued |
Effective date: 20220321 |
|
| FZDE | Discontinued |
Effective date: 20220321 |